Last reviewed · How we verify
NCT06204133
Model Study on Cervical Cancer Screening Strategies and Risk Prediction
trial testing Artificial intelligence model building in Cervical Cancer Screening in 1,112,846 participants. Completed in 30 June 2024.
30 April 2024
Quick facts
| Lead sponsor | Fujian Maternity and Child Health Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,112,846 |
| Start date | 1 November 2023 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 7 locations across China |
Drugs / interventions tested
- Artificial intelligence model building
Conditions studied
- Cervical Cancer Screening — all drugs for Cervical Cancer Screening →
- Risk Assessment — all drugs for Risk Assessment →
- Artificial Intelligence — all drugs for Artificial Intelligence →
- Machine Learning — all drugs for Machine Learning →
Sponsor
Fujian Maternity and Child Health Hospital
Who can join
Adults 25 to 64, female only, with Cervical Cancer Screening or Risk Assessment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
By collecting non-image medical data of women undergoing cervical screening in multiple centers in China, including age, HPV infection status, HPV infection type, TCT results, and colposcopy biopsy pathology results, a multi-source heterogeneous cervical lesion collaborative research big data platform was established. Based on artificial intelligence (AI) machine learning, cervical lesion screening features are refined, a multi-modal cervical cancer intelligent screening prediction and risk triage model is constructed, and its clinical application value is preliminarily explored.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development, validation, and clinical application of a machine learning model for risk stratification and management of cervical cancer screening based on full-genotyping hrHPV test (SMART-HPV): a modelling study.
Dong B, Lu Z, Yang T, Wang J, et al · · 2025 · cited 10× · PMID 39926367 · DOI 10.1016/j.lanwpc.2025.101480
Verify or expand the search:
- PubMed search for NCT06204133
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer Screening
Currently open trials in the same condition.
- NCT06968871 — Ameliorated Pap Tests and Cervical Cancer Screening Participation · NA · recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT07171658 — Breast Cancer-Related Approach for Increasing Cervical Cancer Screening · NA · recruiting
- NCT07581873 — Education and Health in Women With Cervical Cancer · NA · active not recruiting
- NCT07181278 — Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of De · NA · recruiting
Other Fujian Maternity and Child Health Hospital trials
Trials by the same sponsor.
- NCT06276309 — Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors · recruiting
- NCT06137352 — Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity · not yet recruiting
- NCT05932563 — Study on the Epidemiological Characteristics of Female HPV Vaccination in China · unknown
- NCT05745597 — Prognostic Study of HPV Virus Integration in Women With HSIL · unknown
- NCT05932576 — A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06204133 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Maternity and Child Health Hospital
- Last refreshed: 22 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06204133.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing